// App-Quantinova.ai

3017 : Using a pharmacodynamic biomarker led approach to explore and quantify the combination effect of savolitinib and osimertinib in the LG1208 NSCLC PDX model

Researchers

Presenter

  • Rhys Jones

Principal Investigators

  • Awlin Schuller

  • Klas Petersson

  • Ghada Ahmed

  • Stein Schalkwijk

  • Areya Tabatabai

  • Andrew Mortlock

  • Rana Anjum

Medical Centers

  • AstraZeneca, Waltham, MA

  • qPharmetra, Stockholm, Sweden

Locations

  • United Kingdom

  • United States

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Phosphorylated endothelial growth factor receptor

  • Threonine at amino acid position 790

Drug/Treatment

  • Savolitinib

  • Tagrisso

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Fixed Dose

Phase

  • II

Study Id's

  • NCT02143466

  • NCT03778229

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved